These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 26512703)
1. Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data? Górriz JL; Nieto J; Navarro-González JF; Molina P; Martínez-Castelao A; Pallardó LM J Clin Med; 2015 Oct; 4(10):1866-89. PubMed ID: 26512703 [TBL] [Abstract][Full Text] [Related]
2. SGLT2 Inhibitors and the Diabetic Kidney. Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829 [TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection? Cherney DZ; Perkins BA Can J Diabetes; 2014 Oct; 38(5):356-63. PubMed ID: 25192954 [TBL] [Abstract][Full Text] [Related]
4. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes. De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844 [TBL] [Abstract][Full Text] [Related]
5. The kidney and cardiovascular outcome trials. Bloomgarden Z J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006 [TBL] [Abstract][Full Text] [Related]
6. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease. Zou H; Zhou B; Xu G Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711 [TBL] [Abstract][Full Text] [Related]
7. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease. Mima A J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432 [TBL] [Abstract][Full Text] [Related]
8. SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects. Garofalo C; Borrelli S; Liberti ME; Andreucci M; Conte G; Minutolo R; Provenzano M; De Nicola L Medicina (Kaunas); 2019 Jun; 55(6):. PubMed ID: 31212638 [TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury. Penno G; Garofolo M; Del Prato S Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869 [TBL] [Abstract][Full Text] [Related]
10. Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes. Scheen AJ Diabetes Metab; 2019 Apr; 45(2):110-121. PubMed ID: 30477733 [TBL] [Abstract][Full Text] [Related]
13. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Škrtić M; Cherney DZ Curr Opin Nephrol Hypertens; 2015 Jan; 24(1):96-103. PubMed ID: 25470017 [TBL] [Abstract][Full Text] [Related]
14. Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease. Roussel R; Lorraine J; Rodriguez A; Salaun-Martin C Adv Ther; 2015 Nov; 32(11):1029-64. PubMed ID: 26581749 [TBL] [Abstract][Full Text] [Related]
15. Managing the Course of Kidney Disease in Adults With Type 2 Diabetes: From the Old to the New. Goldenberg RM; Berall M; Chan CTM; Cherney DZI; Lovshin JA; McFarlane PA; Senior PA; Verma S; Weinstein JJ Can J Diabetes; 2018 Jun; 42(3):325-334. PubMed ID: 28822777 [TBL] [Abstract][Full Text] [Related]
16. The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin. Kanasaki K Clin Sci (Lond); 2018 Feb; 132(4):489-507. PubMed ID: 29491123 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease. Neumiller JJ; Alicic RZ; Tuttle KR J Am Soc Nephrol; 2017 Aug; 28(8):2263-2274. PubMed ID: 28465376 [TBL] [Abstract][Full Text] [Related]
18. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials. Lee MMY; Petrie MC; McMurray JJV; Sattar N Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025 [TBL] [Abstract][Full Text] [Related]
19. The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes. Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Chattipakorn SC; Chattipakorn N; Lungkaphin A Biomed Pharmacother; 2017 Oct; 94():176-187. PubMed ID: 28759755 [TBL] [Abstract][Full Text] [Related]